A predictive model of polymetastatic disease from a multicenter large retrospectIve database on colorectal lung metastases treated with stereotactic ablative radiotherapy: The RED LaIT-SABR study

Nicosia, Luca; Franceschini, Davide; Perrone-Congedi, Francesca; Molinari, A.; Gerardi, M.A.; Rigo, Michele; Mazzola, Rosario; Perna, Marco; Scotti, Vieri; Fodor, Andrei; Iurato, A.; Pasqualetti, Francesco; Gadducci, G; Chiesa, S.; Niespolo, R.M.; Bruni, Alessio; Cappelli, Anna; D’Angelo, Elisa; Borghetti, Paolo; Marzo, A. Di; Ravasio, A.; Bari, Berardino De; Sepulcri, Matteo; Aiello, D.; Mortellaro, Gianluca; Sangalli, Claudia; Franceschini, Marzia; Montesi, Giampaolo; Aquilanti, F.M.; Lunardi, Gianluigi; Valdagni, Riccardo; Fazio, Ivan; Scarzello, Giovanni; Vavassori, V.; Maranzano, Ernesto; Magrini, Stefano Maria; Arcangeli, Stefano; Gambacorta, Maria Antonietta; Valentini, Vincenzo; Paiar, Fabiola; Ramella, Sara; Muzio, N.G. Di; Loi, Mauro; Jereczek‐Fossa, Barbara Alicja; Casamassima, F.; Osti, Mattia Falchetto; Scorsetti, Marta; Alongi, Filippo

doi:10.1016/j.ctro.2022.100568

Cited by 1 publication

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oligometastatic disease (OMD) is an intermediate state between localized and polimetastatic disease, characterized by a limited number of distant metastases [1,2]. Several factors have been analyzed to identify patients who can benefit more from local treatment, such as number and size of metastases, disease-free interval (DFI), and the rate of distant metastases [3][4][5]. Several OMD subgroups have been identified [6], even though the biologic mechanism behind their generally slower clinical behavior has not been completely elucidated [7].…”

Section: Introductionmentioning

confidence: 99%

Lymph-Nodal Oligometastases from Prostate Cancer: Different Outcomes and Pattern of Relapse between Pelvic and Para-Aortic Disease

Pastorello,

Nicosia,

Triggiani

et al. 2024

Preprint

View full text Add to dashboard Cite

Introduction: Lymph-nodal prostate cancer oligometastases are differently treated according to their site: pelvic are locoregional lymph-nodes, instead para-aortic lymph-nodes are considered as distant metastases. Aim of the study was a comparison between para-aortic and pelvic oligometastases treated with stereotactic body radiation therapy (SBRT). Material/methods: This is a retrospective analysis. De-novo metastatic or extra-nodal disease were excluded. Univariate and multivariate analyses were performed; pattern of recurrence was evaluated too. A propensity score matching (PSM) was applied to create comparable cohorts. Primary end-point was the progression-free survival (PFS). Secondary end-points were biochemical relapse-free survival (BRFS), ADT-free survival (ADTFS), polymetastases-free survival (PMFS), local progression-free survival (LPFS) and pattern of relapse. Results: 240 lymph-nodal oligometastases in 164 patients (127 pelvic and 37 para-aortic) were treated. Median PFS was 20 and 11 months in pelvic and para-aortic patients respectively (p=0.042). The difference was not confirmed at the multivariate analysis (p=0.06). Median BRFS was 16 and 9 months respectively in pelvic and para-aortic group (p=0.07). No statistically significant differences for ADTFS or PMFS were detected. The cumulative 5-years LPFS was 90.5%. At PSM no statistically significant differences for all the study end-points were detected. Conclusions: Patients affected by para-aortic disease might have PFS comparable to pelvic disease; local control is high in both cohorts. Our results support the use of SBRT also to para-aortic metastases.

show abstract